Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells.
Synonymous mutations in the KRAS gene are clustered at G12, G13, and G60 in human cancers. We constructed 9 stable NIH3T3 cell lines expressing KRAS, each with one of these synonymous mutations. Compared to the negative control cell line expressing the wild type human KRAS gene, all the synonymous mutant lines expressed more KRAS protein, grew more rapidly and to higher densities, and were more invasive in multiple assays. Three of the cell lines showed dramatic loss of contact inhibition, were more refractile under phase contrast, and their refractility was greatly reduced by treatment with trametinib. Codon usage at these glycines is highly conserved in KRAS compared to HRAS, indicating selective pressure. These transformed phenotypes suggest that synonymous mutations found in driver genes such as KRAS may play a role in human cancers.
Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.|Biology Department, Catholic University of America, Washington, District of Columbia, United States of America.
Andrew M
AM
Waters
Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
Rachel
R
Bagni
Biology Department, Catholic University of America, Washington, District of Columbia, United States of America.
Franklin
F
Portugal
Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
James L
JL
Hartley
Curr Biol. 2013 Jan 7;23 (1):70-5
23246410
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11
25355519
Cell. 1997 May 2;89(3):457-67
9150145
Cell. 2014 Mar 13;156(6):1324-35
24630730
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3637-40
6285355
Hum Mutat. 2010 Dec;31(12 ):1366-73
20848649
Int J Cancer. 2013 Sep 1;133(5):1259-65
23404247
BMC Cancer. 2009 Jun 23;9:198
19545448
J Clin Invest. 2015 Jan;125(1):222-33
25437878
Cancer Cell. 2009 Jun 2;15(6):489-500
19477428
Retrovirology. 2013 Jul 25;10:78
23885919
Nat Rev Genet. 2011 Aug 31;12(10):683-91
21878961
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
11125122
Science. 1977 Dec 9;198(4321):1056-63
412251
Cancer Discov. 2013 May;3(5):520-33
23365119
Cytotechnology. 2014 Jan;66(1):133-47
23430347
Nat Rev Cancer. 2010 Jan;10 (1):59-64
20029424
Mol Cell. 2015 Jul 16;59(2):149-61
26186290
Science. 2006 Oct 13;314(5797):268-74
16959974
Acta Haematol. 1994;92(3):123-5
7871950
Genome Res. 2000 Nov;10(11):1788-95
11076863
Nat Med. 2011 Dec 06;17(12):1536-8
22146444
Genome Res. 2004 Jun;14(6):1188-90
15173120
Sci Rep. 2015 Jan 20;5:7857
25600636
Biochim Biophys Acta. 2016 Feb;1862(2):155-65
26581171
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6924-8
8692920
Cancer Res. 2002 Dec 15;62(24):7154-6
12499248
J Virol. 2015 Nov;89(21):10762-73
26269186
Mol Microbiol. 2015 Sep;97(5):974-87
26032251
Cancer Cell. 2014 Mar 17;25(3):272-81
24651010
Cancer Cell. 2015 Sep 14;28(3):370-83
26343582
Br J Cancer. 2012 Dec 4;107(12 ):1997-2004
23099803
Curr Biol. 2013 Jan 7;23 (1):R17-20
23305663
Science. 2007 Jan 26;315(5811):525-8
17185560
Science. 2008 Jun 27;320(5884):1784-7
18583614
J Clin Pathol. 2014 Jan;67(1):1-9
24022727
BMC Bioinformatics. 2011 Apr 19;12:107
21504621
Int J Mol Sci. 2013 Jul 02;14 (7):13748-62
23820584
J Biol Chem. 2010 Sep 10;285(37):28741-8
20628052
Nature. 2013 Mar 7;495(7439):111-5
23417067
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13481-6
23901115
Proc Natl Acad Sci U S A. 1985 Jun;82(11):3849-53
2987950
Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
12824337
Cancer Res. 1989 Dec 1;49(23):6474-9
2573414